866-997-4948(US-Canada Toll Free)

Investigation Report on China Letrozole Market, 2010-2019

Published By :

China Research and Intelligence Co., Ltd. (CRI)

Published Date : Aug 2015

Category :

Manufacturing, Packaging & Detailing

No. of Pages : 20 Pages

Currently, breast cancer has become the first killer of women with new cases reaching about 1.2 million and 0.5 million women dying of it each year.

According to Breast Cancer in China which was published in 2014, the number of new cases and deaths in China respectively accounted for 12.2% and 9.6% of the world sum. And the growth rate of China doubled that of the world. According to the statistics, breast cancer with increasing incidence is the most common malignant cancer for Chinese women. And the average age at onset is 10-15 years younger than that in Europe and America. As the third generation of aromatase inhibitor developed by Novartis, letrozole entered United Kingdom first in 1996 and the US in 1997 before being widely used as the first-line drug for advanced breast cancer and as the second-line drug for breast cancer. At home, Jiangsu Hengrui Medicine Co., Ltd was approved to market letrozole under the trade name of Furui in 1999, followed by Femara of Novaris in 2003.

According to CRI

Table of Content

1 Related Concepts of Letrozole
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Letrozole in China
2.1 Patent and Approval Information of Letrozole in China
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Letrozole Sales in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

4 Survey on Market Share of Major Letrozole Manufacturers in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Survey on Dosage Forms of Letrozole in China, 2010-2014

6 Reference Price of Letrozole in Chinese Hospitals in 2014

6.1 Jiangsu Hengrui Medicine Co., Ltd (Trade Name: Furui)
6.2 Novartis AG (Switzerland) (Trade Name: Femara)

7 Major Manufacturers of Letrozole in Chinese Market, 2010-2014
7.1 Jiangsu Hengrui Medicine Co., Ltd
7.2 Novartis AG (Switzerland)

8 Market Outlook of Letrozole in China, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

List of Table

NA

List of Chart


Chart Patent of Letrozole in China
Chart Approval Information of Letrozole in China
Chart Letrozole Sales in China
Chart Sales Value of Letrozole in China, 2010-2014
Chart Sales Value of Letrozole in Some Regions in China, 2010-2014
Chart Sales Volume of Letrozole in China, 2010-2014
Chart Sales Volume of Letrozole in Some Regions in China, 2010-2014
Chart Market Share of TOP2 Letrozole Manufacturers for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Letrozole Made by Novartis (Switzerland) in China, 2010-2014
Chart Sales Value and Market Share of Letrozole Made by Jiangsu Hengrui in China, 2010-2014
Chart Price of Letrozole Made by Jiangsu Hengrui Medicine Co., Ltd in Some Chinese Cities in 2014
Chart Price of Letrozole Made by Novartis AG (Switzerland) in Some Chinese Cities in 2014

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *